Functional Dyspepsia - Pipeline Insight, 2024

This “Functional Dyspepsia - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Functional Dyspepsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Functional Dyspepsia Understanding

Functional Dyspepsia: Overview

Functional dyspepsia is a term assigned for referring to recurring signs and symptoms associated with indigestion with no obvious cause. It is also referred to as nonulcer dyspepsia or nonulcer stomach pain.

Symptoms
Symptoms associated with functional dyspepsia are nausea, an early feeling of fullness, belching, bloating, and a burning sensation in lower chest or upper abdomen.

Diagnosis
Diagnosis is made by conducting a thorough physical exams. Tests such as blood tests, tests for specific bacterium species, and endoscopy may also be carried out.

Treatment
Presently, there is no treatment available for treating functional dyspepsia completely. The condition can be managed by medication, changing lifestyle habits, and a combination of the two. Medications include pan medication, treating helicobacter pylori treatment, and medication aimed at reducing the acid in the stomach.

Functional Dyspepsia Emerging Drugs Chapters

This segment of the Functional Dyspepsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Functional Dyspepsia Emerging Drugs

Naronapride: Renexxion Renexxion’s Naronapride is in the phase II stage of the drug development process. The drug candidate is an orally administered small organic molecule. It was designed to be an effective and selective serotonin 5-HT4 receptor agonist. This works by stimulating the activity of 5-HT4 receptors present in the wall of gut which promotes the release of acetylcholine, thereby increasing the motility of the GItract.

DWJ 1252: Daewoong Pharmaceutical Daewoong Pharmaceutical’s DWJ 1252 is reported to be in the Phase III of the drug development. It belongs to the class of small molecules and follows the mechanism of action of serotonin 4 receptor agonists. It is also known as mosapride sustained releaseformulation.

Functional Dyspepsia: Therapeutic Assessment

This segment of the report provides insights about the different Functional Dyspepsia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Functional Dyspepsia

There are approx. 4+ key companies which are developing the therapies for Functional Dyspepsia. The companies which have their Functional Dyspepsia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Renexxion and others.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Functional Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Functional Dyspepsia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Functional Dyspepsia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Functional Dyspepsia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Functional Dyspepsia R&D. The therapies under development are focused on novel approaches to treat/improve Functional Dyspepsia.

Functional Dyspepsia Report Insights

• Functional Dyspepsia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Functional Dyspepsia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Functional Dyspepsia drugs?
• How many Functional Dyspepsia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Functional Dyspepsia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Functional Dyspepsia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Functional Dyspepsia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Renexxion
• Daewoong Pharmaceutical
• Ra QualiaPharmaceutical

Key Products

• Naronapride
• DWJ 1252
• RQ00000010

This product will be delivered within 2 business days.